WXWensheng Xie

Wensheng Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wensheng Xie has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Quinn Lu

    Novel Human Genetics Research Unit, GlaxoSmithKline, Collegeville, PA, USA

    2 shared publications
  • Hoang Tran

    Research Statistics, GlaxoSmithKline, Collegeville, PA, USA

    1 shared publication
  • Hu Li

    Department of Biological Sciences, Platform Technology and Science, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, USA

    1 shared publication
  • Kathleen Gallagher

    Department of Target & Pathway Validation, Target Sciences, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, USA

    1 shared publication
  • Kathy Johnson

    Department of Target & Pathway Validation, Target Sciences, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, USA

    1 shared publication
  • Michael Ouellette

    Department of Biological Sciences, Platform Technology and Science, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, USA

    1 shared publication

Latest Publications

  • Open Access

    Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery

    by Michael Platchek, Quinn Lu, Hoang Tran, Wensheng Xie


  • A Luciferase Reporter Gene System for High-Throughput Screening of γ-Globin Gene Activators

    by Wensheng Xie, Robert Silvers, Michael Ouellette, Zining Wu, Quinn Lu, Hu Li, Kathleen Gallagher, Kathy Johnson, Monica Montoute

    Luciferase reporter gene assays have long been used for drug discovery due to their high sensitivity and robust signal. A dual reporter gene system contains a gene of interest and a control gene to monitor non-specific effects on gene expression. In our dual luciferase reporter gene system, a synthetic promoter of γ-globin gene was constructed immediately upstream of the firefly luciferase gene, followed downstream by a synthetic β-globin gene promoter in front of the Renilla luciferase gene. A stable cell line with the dual reporter gene was cloned and used for all assay development and HTS work. Due to the low activity of the control Renilla luciferase, only the firefly luciferase activity was further optimized for HTS. Several critical factors, such as cell density, serum concentration, and miniaturization, were optimized using tool compounds to achieve maximum robustness and sensitivity. Using the optimized reporter assay, the HTS campaign was successfully completed and approximately 1000 hits were identified. In this chapter, we also describe strategies to triage hits that non-specifically interfere with firefly luciferase.